Skip to main content

Evrysdi News

Monthly News Roundup - February 2025

FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitation on duration of dosing, allowing...

FDA Approves Tablet Form of Evrysdi for Spinal Muscular Atrophy

TUESDAY, Feb. 18, 2025 – The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA). ...

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

South San Francisco, CA – February 12, 2025 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a ...

FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

SOUTH PLAINFIELD, N.J., May 31, 2022 /PRNewswire/ – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi...

FDA Approves Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older

South San Francisco, CA – August 7, 2020 – Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi (risdiplam) for treatment of...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Spinal Muscular Atrophy

Evrysdi patient information at Drugs.com